Skip to main content

Targeting Cancer with ERV Vaccines

Objective

InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types.
Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.

Coordinator

INPROTHER APS
Net EU contribution
€ 2 500 000,00
Address
Co Bio Innovation Institute, Ole Ma
2200 Kobenhavn
Denmark

See on map

Region
Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 9 679 813,25